Wall Street Researcher
BREAKOUT ALERT
HUMANIGEN INC
HGEN NASDAQ
MASSIVE SHORT COVERING EXPECTED
Initiate BUY – Upside Volitility
Cantor Fitzgerald – $2.00 Target
Shorts Run for Cover -These Eight Stocks Are Hot
SHORTS MAY RUN FOR COVER DRIVING THESE SHARES HIGHER
These shares are trading significantly below its intrinsic value after being we feel illegally shorted by one or more professional shorters. Biotech is the favorite target of institutional shorters whose only goal is to short a stock into submission cutting them off from its traditional financial sources.
Credit Suisse – Roth Capital,- HC Wainwright- Cantor Fitzgerald before July 2022 all carried these shares as a BUY with target prices as high as $30 . Cantor Fitzgerald has set their new target price to $2.00 after the sharp drop.
These shares fell precipitously from $3.00 to its low of $0.10 cents due to the failure of a Covid trial on one of its drugs, Lenzilumab in July 2022. Other trials for other drugs and diseases are currently underway with these shares significantly in an oversold condition.
We urge all serious traders to watch for a massive short covering and to immediately place these shares on their WATCH LIST . We look for a test of the of the 200 day M/A at $1.53 followed by a test of $2.00 price target by Cantor Fitzgerald
***********************************************
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), is a clinical-stage biopharmaceutical company focused on preventing and treating certain inflammatory and oncological conditions with its product candidates, lenzilumab and ifabotuzumab. Lenzilumab is a Humaneered® monoclonal antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF).
Results from preclinical models indicate GM-CSF is an upstream regulator of many inflammatory cytokines and chemokines. Humanigen is exploring the effectiveness of lenzilumab as a treatment for chronic myelomonocytic leukemia and other inflammatory conditions such as Acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and as a companion therapy for patients receiving CD19 targeted CAR-T cell therapies.
Ifabotuzumab (Anti-EphA3) is a Humaneered® monoclonal antibody targeting tumor vasculature. EphA3 has broad expression in human tumors. Initial area of emphasis may include breast carcinoma, non-small cell lung carcinoma, pancreatic carcinoma and glioblastoma multiforme. For more information, visit www.humanigen.com and follow Humanigen on LinkedIn, Twitter, and Facebook.
About Humanigen, Inc.
Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), is a clinical-stage biopharmaceutical company focused on developing lenzilumab, a first-in-class antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor. Humanigen is developing lenzilumab as a treatment for chronic myelomonocytic leukemia and acute graft versus host disease. Humanigen is also exploring use of lenzilumab to prevent toxicities associated with CAR-T therapy through investigator-initiated trials. Humanigen is also developing an antibody drug conjugate (ADC) utilizing its EphA-3 targeted monoclonal antibody ifabotuzumab (ifab) for solid tumors. For more information, visit www.humanigen.com and follow Humanigen on Twitter.
Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward-looking statements reflect management’s current knowledge, assumptions, judgment, and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct, and you should be aware that actual events or results may differ materially from those contained in the forward- looking statements. Words such as “will,” “expect,” “intend,” “plan,” “potential,” “possible,” “goals,” “accelerate,” “continue,” and similar expressions identify forward-looking statements.
Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital to continue as a going concern; our ability to successfully execute the strategic realignment of our pipeline and resources; our ability to identify and execute upon a strategic transaction to maximize value for our stakeholders; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory authorizations and approvals and launch of any new pharmaceutical product; the outcome of pending or future litigation or arbitration; and the various risks and uncertainties described in the “Risk Factors” sections of our latest annual and quarterly reports and other filings with the SEC.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not rely upon any forward-looking statements as predictions of future events. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof, to reflect new information or the occurrence of unanticipated events, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, in each case, except as required by law
Neither PSN or WSR nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is not a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN or WSR website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN or WSR website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN or WSR website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.. All Reports are reviewed for accuracy and concur that any conclusions made are reasonable expectations. The term Buy List referring to a Watch List and not a recommendation to buy . Each individual has their own risk level and should know their risk level and act accordingly . WRITER OWNES 100,000 SHARES AT AN AVERAGE COST OF $0.274